Novartis: all 3,900 studies
Page 25 of 39. Open to participants first (226), then studies with results posted, then the rest; newest registration first within each.
- Safety Study of LLF580 in Obese VolunteersCompletedNCT03466203Phase 1
- Determine the Safety, Tolerability, and Efficacy of MAU868 for the Prevention of BK Virus Infection in Kidney Transplant RecipientsWithdrawnNCT03456999Phase 2
- Long-Term Follow-up Study for Patients From AVXS-101-CL-101Active, not recruitingNCT03421977
- A Study Comparing Two Ferric Carboxymaltose Formulations in Patients With Iron Deficiency AnemiaCompletedNCT03399084Phase 1
- Efficacy and Safety of MAA868 in Patients With Atrial FibrillationWithdrawnNCT03398434Phase 2
- Prevention of Thromboembolic Events in Total Knee Replacement PatientsWithdrawnNCT03393481Phase 2
- Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart FailureCompletedNCT03387163
- LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)WithdrawnNCT03377426Phase 2
- A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis PigmentosaCompletedNCT03374657Phase 1/2
- A Study to Evaluate CSJ148 in Pregnant Women With Primary HCMV InfectionWithdrawnNCT03369912Phase 2
- First-in-human, Safety, Tolerability and Pharmacokinetics Study of LRX712 in Osteoarthritic PatientsCompletedNCT03355196Phase 1
- Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)TerminatedNCT03333694Phase 1
- Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLCActive, not recruitingNCT03333343Phase 1
- Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced MalignanciesTerminatedNCT03301896Phase 1
- Safety and PK Trial Evaluating the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Minocin IVWithdrawnNCT03291158Phase 1
- Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)WithdrawnNCT03240393Phase 2
- ADCC Mediated B-Cell dEpletion and BAFF-R BlockadeCompletedNCT03217422Phase 2/3
- PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal CancerTerminatedNCT03176264Phase 1
- Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or LymphomasTerminatedNCT03172936Phase 1
- A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7)CompletedNCT03159416Phase 1
- A Bronchoprovocation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CSJ117 in Adult Subjects With Mild Atopic AsthmaCompletedNCT03138811Phase 1
- Dose Finding Study of TNO155 in Adult Patients With Advanced Solid TumorsTerminatedNCT03114319Phase 1
- An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)No longer availableNCT03114228
- Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple MyelomaCompletedNCT03111992Phase 1
- Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy SubjectsCompletedNCT03087942Phase 1
- Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal CancerCompletedNCT03081494Phase 1
- Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast CancerWithdrawnNCT03081234Phase 3
- Urine, DNA and Clinical Information Collection From Patients With Alport Nephropathy.CompletedNCT03074357
- High Myopia: Extended and Longterm Observation of Pathologic Myopia Patients With the Risk for Developing a Myopic Choroidal Neovascularization (CNV)CompletedNCT03070717
- Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)WithdrawnNCT03070691Phase 2/3
- Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDSCompletedNCT03066648Phase 1
- PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC PatientsTerminatedNCT03064854Phase 1
- Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy SubjectsCompletedNCT03048448Phase 1
- Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment AloneActive, not recruitingNCT03040973Phase 2
- An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing SurgeryCompletedNCT03011320Phase 1
- Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple MyelomaCompletedNCT02992483Phase 1
- Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular PatientsCompletedNCT02988440Phase 1
- Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki DiseaseWithdrawnNCT02980263Phase 2
- A Phase Ib Study of LXH254-centric Combinations in NSCLC or MelanomaTerminatedNCT02974725Phase 1
- Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentActive, not recruitingNCT02962414Phase 3
- PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNadaCompletedNCT02957409
- Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.CompletedNCT02947165Phase 1
- HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell CarcinomaTerminatedNCT02947152Phase 1
- A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.TerminatedNCT02936102Phase 1
- Ribociclib (LEE011) Rollover Study for Continued AccessActive, not recruitingNCT02934568Phase 2
- A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.CompletedNCT02925104Phase 1
- Optical Coherence Tomography (OCT) Trial in Multiple SclerosisCompletedNCT02907281
- A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)CompletedNCT02900664Phase 1
- Safety and Efficacy of MAK683 in Adult Patients With Advanced MalignanciesTerminatedNCT02900651Phase 1
- A Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatCompletedNCT02890069Phase 1
- 24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.WithdrawnNCT02878681Phase 4
- Study in End-stage Renal Disease Patients Awaiting Kidney Transplant to Investigate the Potential Effect of IVIG Treatment on the Pharmacokinetics and Pharmacodynamics of LFG316CompletedNCT02878616Phase 1
- Pharmacokinetics of Dabrafenib in Subjects With Hepatic ImpairmentTerminatedNCT02873650Phase 1
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular EdemaCompletedNCT02867735Phase 1
- A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired SubjectsCompletedNCT02857868Phase 1
- Pharmacokinetics of Dabrafenib in Subjects With Renal ImpairmentCompletedNCT02852239Phase 1
- A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid LeukemiaWithdrawnNCT02826642Phase 1
- Study to Investigate the Safety and Efficacy of 3 Dosing Regimens of ABP-700 for Procedural Sedation in Adult Participants Undergoing ColonoscopyCompletedNCT02800590Phase 2
- Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish PopulationWithdrawnNCT02795416Phase 3
- A Registry of Patients With Moderate to Severe Plaque PsoriasisCompletedNCT02786186
- Determination of Accuracy in Measurement of Total Immunoglobulin E Using a Test Device in Atopic SubjectsCompletedNCT02758548Phase 2
- Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple MyelomaWithdrawnNCT02756663Phase 2
- Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted TherapyCompletedNCT02753686
- Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and LymphomasCompletedNCT02740270Phase 1
- Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast CancersTerminatedNCT02734615Phase 1
- Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD)WithdrawnNCT02715505Phase 1/2
- A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid TumorsCompletedNCT02705963Phase 1
- EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA TxApproved for marketingNCT02705313
- Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid TumorsTerminatedNCT02703571Phase 1
- Phase I Study of PDR001 in Patients With Advanced Malignancies.CompletedNCT02678260Phase 1
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of VAY736 in Rheumatoid Arthritis PatientsCompletedNCT02675803Phase 1
- Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or LymphomasTerminatedNCT02675439Phase 1
- Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLCWithdrawnNCT02672358Phase 2
- CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumabWithdrawnNCT02634970Phase 4
- A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid TumorsCompletedNCT02626234Phase 1
- A Worldwide Antihistamine-Refractory Chronic Urticaria Patient Evaluation in Latin America and Canada (AWARE-LACan)CompletedNCT02626221
- Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation ChemotherapyNo longer availableNCT02624570
- Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.CompletedNCT02624557Phase 1
- Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway AlterationsTerminatedNCT02607813Phase 1
- Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque PsoriasisCompletedNCT02607774Phase 1
- Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCLCompletedNCT02603445Phase 1
- A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.TerminatedNCT02601378Phase 1
- Global Non-interventional Heart Failure Disease RegistryTerminatedNCT02595814
- Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored StudyActive, not recruitingNCT02584933Phase 4
- A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis PatientsCompletedNCT02570854Phase 1
- An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple MyelomaNo longer availableNCT02568943
- Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to MosquitosTerminatedNCT02543086Phase 1
- A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid TumorsCompletedNCT02520752Phase 1
- Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's SyndromeWithdrawnNCT02495129Phase 1/2
- First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee ReplacementCompletedNCT02491281Phase 1
- INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic FunctionCompletedNCT02474537Phase 1
- Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy VolunteersCompletedNCT02471690Phase 1
- A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET AmplificationTerminatedNCT02468661Phase 1
- A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic CancersTerminatedNCT02452268Phase 1
- AWARE - Chronic UrticariaCompletedNCT02435238
- Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011CompletedNCT02431481Phase 1
- A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced TumorsCompletedNCT02422589Phase 1
- A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal FunctionCompletedNCT02399202Phase 1
- Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung CancerActive, not recruitingNCT02393625Phase 1
- Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)No longer availableNCT02389933